JP2023531683A5 - - Google Patents
Info
- Publication number
- JP2023531683A5 JP2023531683A5 JP2022579019A JP2022579019A JP2023531683A5 JP 2023531683 A5 JP2023531683 A5 JP 2023531683A5 JP 2022579019 A JP2022579019 A JP 2022579019A JP 2022579019 A JP2022579019 A JP 2022579019A JP 2023531683 A5 JP2023531683 A5 JP 2023531683A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- patient
- treatment
- melanoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063041989P | 2020-06-21 | 2020-06-21 | |
| US202063041986P | 2020-06-21 | 2020-06-21 | |
| US202063041990P | 2020-06-21 | 2020-06-21 | |
| US202063041991P | 2020-06-21 | 2020-06-21 | |
| US202063041988P | 2020-06-21 | 2020-06-21 | |
| US63/041,986 | 2020-06-21 | ||
| US63/041,990 | 2020-06-21 | ||
| US63/041,989 | 2020-06-21 | ||
| US63/041,991 | 2020-06-21 | ||
| US63/041,988 | 2020-06-21 | ||
| US202163172560P | 2021-04-08 | 2021-04-08 | |
| US63/172,560 | 2021-04-08 | ||
| PCT/US2021/038264 WO2021262604A2 (en) | 2020-06-21 | 2021-06-21 | Administration of cebp-beta antagonist and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023531683A JP2023531683A (ja) | 2023-07-25 |
| JP2023531683A5 true JP2023531683A5 (cg-RX-API-DMAC7.html) | 2025-01-20 |
| JP7880618B2 JP7880618B2 (ja) | 2026-06-26 |
Family
ID=79281738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022579019A Active JP7880618B2 (ja) | 2020-06-21 | 2021-06-21 | CEBP-βアンタゴニストの投与及び使用方法 |
Country Status (17)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119997967A (zh) * | 2022-10-07 | 2025-05-13 | 智慧疗法有限公司 | C/EBP-β拮抗剂和免疫调节剂的使用 |
| WO2024216238A2 (en) * | 2023-04-13 | 2024-10-17 | Sapience Therapeutics, Inc. | Use of beta-catenin antagonist and immunomodulator |
| EP4694911A2 (en) * | 2023-04-13 | 2026-02-18 | Sapience Therapeutics, Inc. | Administration of a beta-catenin antagonist and methods of use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105228642A (zh) * | 2013-02-22 | 2016-01-06 | 纽约市哥伦比亚大学理事会 | 通过抑制转录因子atf5来抑制肿瘤细胞的组合物和方法 |
| CA2983030A1 (en) * | 2015-04-16 | 2016-10-20 | Alder Biopharmaceuticals, Inc. | Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia |
| WO2018152446A2 (en) | 2017-02-20 | 2018-08-23 | Sapience Therapeutics, Inc. | Cell-penetrating atf5 polypeptides and uses thereof |
| PT3737399T (pt) | 2018-01-03 | 2023-09-04 | Sapience Therapeutics Inc | Variantes do péptido atf5 e as respetivas utilizações |
| WO2020033555A2 (en) * | 2018-08-08 | 2020-02-13 | The Trustees Of Columbia University In The City Of New York | Dominant negative cebpb and cebpd proteins and methods of use for decreasing viability of neoplastic cells |
-
2021
- 2021-06-21 AU AU2021297172A patent/AU2021297172B2/en active Active
- 2021-06-21 WO PCT/US2021/038264 patent/WO2021262604A2/en not_active Ceased
- 2021-06-21 CA CA3180559A patent/CA3180559A1/en active Pending
- 2021-06-21 DK DK21828902.3T patent/DK4168033T3/da active
- 2021-06-21 BR BR112022025880A patent/BR112022025880A2/pt unknown
- 2021-06-21 KR KR1020227044587A patent/KR20230027054A/ko active Pending
- 2021-06-21 FI FIEP21828902.3T patent/FI4168033T3/fi active
- 2021-06-21 EP EP21828902.3A patent/EP4168033B1/en active Active
- 2021-06-21 PT PT218289023T patent/PT4168033T/pt unknown
- 2021-06-21 ES ES21828902T patent/ES3066151T3/es active Active
- 2021-06-21 MX MX2022016478A patent/MX2022016478A/es unknown
- 2021-06-21 IL IL299104A patent/IL299104A/en unknown
- 2021-06-21 NZ NZ795026A patent/NZ795026A/en unknown
- 2021-06-21 JP JP2022579019A patent/JP7880618B2/ja active Active
- 2021-06-21 US US18/011,171 patent/US20230218717A1/en active Pending
- 2021-06-21 CN CN202180044276.8A patent/CN115768458A/zh active Pending
-
2022
- 2022-12-05 ZA ZA2022/13167A patent/ZA202213167B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Krishnan et al. | Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177 | |
| Franke et al. | Role of bevacizumab for treatment-refractory meningiomas: A systematic analysis and literature review | |
| JP6351597B2 (ja) | 非転移性去勢抵抗性前立腺癌の治療のための抗アンドロゲン剤 | |
| Rochet et al. | Melanoma brain metastases and vemurafenib: need for further investigation | |
| Aquilanti et al. | Immune checkpoint inhibitors for brain metastases: a primer for neurosurgeons | |
| CN105916501A (zh) | 用于治疗局部晚期或转移性雌激素受体阳性乳腺癌的雌激素受体调节剂 | |
| EP4168008B1 (en) | A combination of belzutifan and lenvatinib for use in treating cancer | |
| AU2021297172B2 (en) | Administration of CEBPβ antagonist and methods of use | |
| Gligorov et al. | Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer | |
| US20210046106A1 (en) | Methods of treating cancer with androgen deprivation therapy in combination with an inhibitor of the sp1 transcription factor | |
| RU2858600C2 (ru) | Способы лечения рака или болезни фон-гиппеля-линдау с использованием комбинации ингибитора hif-2 альфа и ленватиниба или его фармацевтически приемлемой соли | |
| WO2020210829A1 (en) | Methods of promoting long-term survival of patients with advanced chemotherapy-resistant malignancies | |
| von Spreckelsen et al. | DDIS-36. BTP-7, A NOVEL PEPTIDE FOR THERAPEUTIC TARGETING OF MALIGNANT BRAIN TUMORS | |
| Shen et al. | Changjun Wang1, Yan Lin1, Yidong Zhou1, Feng Mao1, Hanjiang Zhu2, Jinghong Guan1, Xiaohui Zhang1 | |
| WO2024077297A2 (en) | Use of c/ebp-beta antagonist and immunomodulator | |
| Buxton et al. | RTID-11. GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA | |
| WO2025068348A1 (en) | Pharmaceutical combination of cxcr4 and pd-1 inhibitors for treating cancer | |
| HK40087480A (en) | Methods for treating cancer or von-hippel lindau disease using a combination of a hif-2 alpha inhibitor and lenvatinib | |
| EP4694911A2 (en) | Administration of a beta-catenin antagonist and methods of use | |
| Akimoto et al. | Radiation Oncology and Molecular-Targeted Therapy for EGFR and its Signal Transduction Pathways: Molecular Basis and Clinical Application for Improvement of Radiotherapeutic Outcomes | |
| Shabaya et al. | Novel therapeutic strategies and combinations for HER2-overexpressing breast cancer | |
| Ray-Coquard et al. | Methods: Eligible patients had high-grade PROC with≤ 4 prior lines of chemotherapy. Weekly paclitaxel (80 mg/m²) and increasing doses of ganetespib (100, 150 mg/m²) were given iv on days 1, 8, 15 in a 28 days cycle until disease progression or unacceptable toxicity. Endpoints were safety and determination of phase II dose. Dose limiting toxicity (DLT) was defined as grade 4 toxicity (with exceptions) occurring in cycles 1&2. |